Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Saved in:
| Title: | Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. |
|---|---|
| Authors: | Cohn, David E.1 David.Cohn@osumc.edu, Sill, Michael W.2 msill@gogstats.org, Walker, Joan L.3 joan-walker@ouhsc.edu, O'Malley, David1 omalley.46@osu.edu, Nagel, Christa I.4 Christa.Nagel@uhhospitals.org, Rutledge, Teresa L.5 trutledge@salud.unm.edu, Bradley, William6 wbradley@mcw.edu, Richardson, Debra L.7 Debra.richardson@utsouthwestern.edu, Moxley, Katherine M.3 katherine-moxley@ouhsc.edu, Aghajanian, Carol8 aghajanc@mskcc.org |
| Source: | Gynecologic Oncology. Sep2017, Vol. 146 Issue 3, p477-483. 7p. |
| Database: | Academic Search Ultimate |
| ISSN: | 00908258 |
|---|---|
| DOI: | 10.1016/j.ygyno.2017.07.135 |
